10-Q: Medicale Corp. Reports Q2 2024 Results: Minimal Assets, Continued Losses, and Going Concern Concerns

Medicale Corp.'s Q2 2024 filing reveals minimal assets, ongoing losses, and substantial doubt about its ability to continue as a going concern.

Summary

• Medicale Corp. filed its Form 10-Q for the quarter ended March 31, 2024.
• The company has minimal assets, with total assets of $159 as of March 31, 2024, consisting solely of cash.
• The company reported a net loss of $11,564 for the three months ended March 31, 2024, and $30,871 for the six months ended March 31, 2024.
• Operating expenses mainly consist of professional fees.
• The company has an accumulated deficit of $148,503 as of March 31, 2024.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company intends to raise additional funds through the capital markets.
• The company's disclosure controls and procedures were deemed not effective as of March 31, 2024.
• The company entered into convertible note agreements with third parties totaling $58,788.
• The company has not commenced any significant operations as of the date of the report.

Sentiment

Score: 2

Explanation: The document presents a negative outlook due to the company's minimal assets, continued losses, going concern uncertainty, and ineffective disclosure controls.

Positives

• The company secured $58,788 in financing through convertible notes.

Negatives

• The company has minimal assets, with only $159 in cash.
• The company continues to incur net losses, with a $30,871 loss for the six months ended March 31, 2024.
• The accumulated deficit has grown to $148,503.
• The company's disclosure controls and procedures are not effective.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company's disclosure controls and procedures are not effective, indicating potential weaknesses in financial reporting.
• The company is dependent on raising additional capital, which may not be available on acceptable terms or at all.
• Additional issuances of equity or convertible debt securities will result in dilution to current shareholders.
• The COVID-19 pandemic could have a material adverse impact on the company's business, financial condition, and results of operations.

Future Outlook

The company expects to require additional capital to meet its long-term operating requirements and intends to raise additional capital through the sale of equity or debt securities.

Management Comments

• Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses.
• Management expects that its business will be impacted to some degree by the COVID-19 outbreak.

Industry Context

Given the lack of revenue and reliance on future capital raises, Medicale Corp.'s financial situation is not uncommon for early-stage companies in the dietary supplement or consulting services industries. Many such companies face challenges in securing funding and achieving profitability.

Comparison to Industry Standards

• It is difficult to compare Medicale Corp.'s performance to industry standards due to its lack of operations and revenue.
• Many early-stage companies in similar industries, such as dietary supplements or consulting, often rely on venture capital or angel investors for funding.
• Companies like NutraLife BioSciences or consulting firms like Accenture have significantly larger asset bases and revenue streams, making direct comparisons unfeasible at this stage.

Management Changes

Related Party Transactions

• As a result of the acquisition of the Shares on December 28, 2022, the previous majority shareholder of Medicale Corp. (the Company) Borisi Alborovi forgive the debt that due to him, with the amount of $ 51,192.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• The company's ability to continue operations is uncertain, potentially impacting stakeholders.
• The company's ineffective disclosure controls could affect the reliability of financial information available to stakeholders.

Next Steps

• The company intends to position itself to raise additional funds through the capital markets.
• The company will seek to obtain short-term loans from its directors.
• The company will continue to seek additional funding in the form of equity financing from the sale of its common stock.

Key Dates

Keywords

financial statements, going concern, convertible note, net loss, Medicale Corp, Form 10-Q